Fabry disease: a review of current enzyme replacement strategies

Bibliography

• Mehta A, Hughes DA. Fabry disease: Gene Review. NCBI Bookshelf [Last accessed 1 May 2015]
   Google Scholar
• Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the fabry outcome survey. Eur J Clin Invest 2004;34:236-42
   PubMed Web of Science ®Google Scholar
• Thomas A.S, Mehta AB. Difficulties and barriers in diagnosing Fabry disease: what can be learnt from the literature? Expert Opinion Med Diagn 2013;6:589-99
   Google Scholar
• Marchesoni CL, Roa N, Pardal AM, et al. Misdiagnosis in Fabry disease. J Pediatr 2010;156(5):828-31
   PubMed Web of Science ®Google Scholar
• Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999;281:249-54
   PubMed Web of Science ®Google Scholar
• Spada M, Pagliardini S, Yasuda M, et al. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 2006;79:31-40
   PubMed Web of Science ®Google Scholar
• Mechtler TP, Stary S, Mez TF, et al. Neonatal screening for lysosomal storage disorders; Feasilbility and incidence from a nationwide study in Austria. Lancet 2012;379:9813-335-41
   Web of Science ®Google Scholar
• Lin HY, Chong KW, Hsu JH, et al. High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. Circ Cardiovasc Genet 2009;2:450-6
   PubMed Web of Science ®Google Scholar
• Deegan PB, Baehner AF, Barba Romero MA, et al. Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet 2006;43:347-52
   PubMed Web of Science ®Google Scholar
• Wilcox WR, Oliveira JP, Hopkin RL, et al. Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry. Mol Genet Metab 2008;93:112-28
   PubMed Web of Science ®Google Scholar
• Echevarria L, Benistan K, Toussaint A, et al. X chromosome inactivation in female patients with Fabry disease. Clin Genet 2015. [Epub ahead of print]
   PubMedGoogle Scholar
• Aerts JM, Groener JE, Kuiper S, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA 2008;105:2812-17
   PubMed Web of Science ®Google Scholar
• Mehta A, Clarke JTR, Giugliani R, et al. Natural course of Fabry disease: changing pattern of causes of death in FOS- Fabry Outcome Survey. J Med Genet 2009;46:548-52
   PubMed Web of Science ®Google Scholar
• Waldek S, Patel MR, Banikazemi M, et al. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med 2009;11:790-6
   PubMed Web of Science ®Google Scholar
• Waldek S, Feriozzi S. Fabry nephropathy: a review-how can we optimize the management of Fabry nephropathy? BMC Nephrol 2014;15:72-87
   PubMed Web of Science ®Google Scholar
• Desnick RJ, Brady R, Barranger J, et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003;138:338-46
   PubMed Web of Science ®Google Scholar
• Eng CM, Germain DP, Banikazemi M. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 2006;8:539-48
   PubMed Web of Science ®Google Scholar
• Biegstraaten M, Arngrímsson R, Barbey F, et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis 2015;10(1):36
   PubMed Web of Science ®Google Scholar
• Al-Thihli K, Ebrahim H, Hughes DA, et al. A variant of unknown significance in the GLA gene causing diagnostic uncertainty in a young female with isolated hypertrophic cardiomyopathy. Gene 2012;497(2):320-2
   PubMed Web of Science ®Google Scholar
• Niemann M, Rolfs A, Störk S, et al. Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease. Circ Cardiovasc Genet 2014;7:8-16
   PubMed Web of Science ®Google Scholar
• Hsu TR, Sung SH, Change FP, et al. Endomyocardial biopsies in patients with left ventricular hypertrophy and a common later-onset Fabry mutation (IV54+919G>A). Orphanet J Rare Dis 2014;9:96
   PubMed Web of Science ®Google Scholar
• Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry’s disease. N Engl J Med 2001;345:9-16
   PubMed Web of Science ®Google Scholar
• Schiffman R, Kopp JB, Austin HA, et al. Enzyme replacement in fabry Disease: a randomised controlled trial. JAMA 2001;285:2743-9
   PubMed Web of Science ®Google Scholar
• Rombach SM, Smid BE, Linthost GE, et al. Natural Course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis. J Inherit Metab Dis 2014;37:341-52
   PubMed Web of Science ®Google Scholar
• Lidove O, West ML, Pintos-Morell G, et al. Effects of enzyme replacement therapy in Fabry disease – A comprehensive review of the medical literature. Genet Med 2010;12(11):668-79
   PubMed Web of Science ®Google Scholar
• El Dib RP, Nascimento P, Pastores GM. Enzyme replacement therapy for Anderson Fabry disease. Cochrane Database Syst Rev 2013;CD006663
   PubMedGoogle Scholar
• Pisani A, Visciano B, Roux GD, et al. Enzyme replacement therapy for Fabry disease; State of the Art and review of the literature. Mol Genet Metab 2012;107(3):267-75
   PubMed Web of Science ®Google Scholar
• Auray-Blais C, Blais C, Ramaswami U, et al. Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry. Clin Chim Acta 2014;438:195-204
   PubMed Web of Science ®Google Scholar
• Deegan PB. Fabry disease: enzyme replacement therapy and the significance of antibody responses. J Inherit Metab Dis 2012;35(2):227-43
   PubMed Web of Science ®Google Scholar
• Linthorst GE, Hollak C, Donker-Koopman WE, et al. Enzyme therapy for Fabry Disease. Neutralizing antibodies toward agalsidase alpha and beta. Kidney Int 2004;66:1589-95
   PubMed Web of Science ®Google Scholar
• Hughes DA, Elliott PM, Shah J, et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomized, double-blind, placebo-controlled clinical trial of agalsidase-alfa. Heart 2008;94:153-8
   PubMed Web of Science ®Google Scholar
• Banikazemi M, Bultas J, Waldek S, et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 2007;146:77-86
   PubMed Web of Science ®Google Scholar
• Germain DP, Charrow J, Desnick RJ, et al. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet 2015;52(5):353-8
   PubMed Web of Science ®Google Scholar
• Eng CM, Fletcher J, Wilcox WR, et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 2007;30:184-92
   PubMed Web of Science ®Google Scholar
• Warnock DG, Ortiz A, Mauer M, et al. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrol Dial Transplant 2012;3:1042-9
   Web of Science ®Google Scholar
• Germain DP, Weidemann F, Abiose A, et al. Analysis of left ventricular mass in untreated men and in men treated with agalsidase beta: Data from the Fabry Registry. Genet Med 2013;15(12):958-65
   PubMed Web of Science ®Google Scholar
• Beck M, Ricci R, Widmer U, et al. Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest 2004;34:838-44
   PubMed Web of Science ®Google Scholar
• West M, Nicholls K, Mehta A, et al. Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol 2009;20:1132-9
   PubMed Web of Science ®Google Scholar
• Mehta A, Beck M, Elliott P, et al. Enzyme replacement therapy with agalsidase alfa in patients with Fabry’s disease: an analysis of registry data. Lancet 2009;374(9706):1986-96
   PubMed Web of Science ®Google Scholar
• Beck M, Hughes D, Kampmann C, et al. Long Term effectiveness of agalsidase alfa enzyme replacement therapy in Fabry disease: a fabry outcome survey analysis. Mol Genet Metab Rep 2015;3:21-7
   PubMed Web of Science ®Google Scholar
• Schiffmann R, Warnock DG, Banikazemi M, et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 2009;24:2102-11
   PubMed Web of Science ®Google Scholar
• Kampmann C, Linhart A, Baehner F, et al. Onset and progression of the Anderson-Fabry disease related cardiomyopathy. Int J Cardiol 2008;130:367-73
   PubMed Web of Science ®Google Scholar
• Hajioff D, Enever Y, Quiney R, et al. Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy. J Inherit Metab Dis 2003;26:787-94
   PubMed Web of Science ®Google Scholar
• Hajioff D, Hegemann S, Conti G, et al. Agalsidase alpha and hearing in Fabry disease: data from the Fabry Outcome Survey. Eur J Clin Invest 2006;36:663-7
   PubMed Web of Science ®Google Scholar
• Schiffmann R, Floeter MK, Dambrosia JM, et al. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve 2003;28:703-10
   PubMed Web of Science ®Google Scholar
• Hoffmann B, Schwarz M, Mehta A, Keshav S; Fabry Outcome Survey European Investigators. Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Clin Gastroenterol Hepatol 2007;5:1447-53
   PubMed Web of Science ®Google Scholar
• Hoffmann B, Beck M, Sunder-Plassmann G, et al. Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy–a retrospective analysis from the Fabry Outcome Survey. Clin J Pain 2007;23:535-42
   PubMed Web of Science ®Google Scholar
• Hoffmann B, Garcia de Lorenzo A, Mehta A, et al. Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey). J Med Genet 2005;42:247-52
   PubMed Web of Science ®Google Scholar
• Feriozzi S, Torras J, Cybulla M, et al. The effectiveness of long term agalsidase alpha in the treatment of Fabry nephropathy. Clin J Am Soc Nephrol 2012;71:60-9
   Web of Science ®Google Scholar
• Cybulla M, Kurschat C, West M, et al. Kidney transplantation and enzyme replacement therapy in patients with Fabry disease. J Nephrol 2013;26(4):645-61
   PubMed Web of Science ®Google Scholar
• Sirrs SM, Bichet DG, Casey R, et al. Outcomes of patients treated through the Canadian Fabry disease initiative. Mol Genet Metab 2014;11(4):499-506
   Web of Science ®Google Scholar
• Vedder AC, Linthorst GE, Houge G, et al. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS One 2007;2:e598
   PubMed Web of Science ®Google Scholar
• Mehta A, Beck M, Kampmann C, et al. Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta. Mol Genet Metab 2008;95:114-15
   PubMed Web of Science ®Google Scholar
• Anderson LJ, Wyatt KM, Henley W, et al. Long term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study. J Inherit Metab Dis 2014;37(6):969-78
   PubMed Web of Science ®Google Scholar
• Weidemann F, Niemann M, Stork S, et al. Evidence for disease progression towards serious complications. J Intern Med 2013;274(4):331-41
   PubMed Web of Science ®Google Scholar
• Weidemann F, Niemann M, Breunig F, et al. Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 2009;119:524-9
   PubMed Web of Science ®Google Scholar
• Mehta AB. Fabry Disease: Is there a role for Enzyme replacement therapy? J Intern Med 2013;274(4):329-30
   PubMed Web of Science ®Google Scholar
• Germain DP, Waldek S, Banikazemi M, et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 2007;18:1547-57
   PubMed Web of Science ®Google Scholar
• Kramer J, Niemann M, Stork S, et al. Relation of burden of myocardial fibrosis to malignant ventricular arrhythmias and outcomes in Fabry disease. Am J Cardiol 2104;114:895-900
   Google Scholar
• Patel V, O’Mahony C, Hughes D, et al. Clinical and genetic predictors of major cardiac events in patients with Anderson–Fabry Disease. Heart 2015;101(12):961-6
   PubMed Web of Science ®Google Scholar
• Pica S, Sado DM, Maestrini V, et al. Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2014;16:99
   PubMed Web of Science ®Google Scholar
• Sado DM, White SK, Piechnik SK, et al. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging 2013;6(3):392-8
   PubMed Web of Science ®Google Scholar
• Sado DM, Flett AS, Banypersad SM, et al. Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease. Heart 2012;98(19):1436-41
   PubMed Web of Science ®Google Scholar
• Coats CJ, Parisi V, Ramos M, et al. Role of serum N-terminal pro-brain natriuretic peptide measurement in diagnosis of cardiac involvement in patients with Anderson Fabry disease. Am J Cardiol 2013;111(1):111-17
   PubMed Web of Science ®Google Scholar
• Prabakaran T, Birn H, Bibby BM, et al. Long term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease. Nephrol Dial Transplant 2014;29(3):619-25
   PubMed Web of Science ®Google Scholar
• EMEA Assessment report for Fabrazyme (algasidase beta). EMEA/H/C/000370 Available from: www.ema.europa.eu/docs/en_GB/document_library/other/2010/11/WC500099241
   Google Scholar
• Linthorst GE, Germain DP, Hollak CE, et al. Expert opinion on temporary treatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT). Mol Genet Metab 2011;102(1):99-102
   PubMed Web of Science ®Google Scholar
• Lubanda JC, Anijalg E, Bzdúch V, et al. Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease. Genet Med 2009;11(4):56-64
   Web of Science ®Google Scholar
• Goker-Alpan O, Nedd K, Shanker SP, et al. Effect and tolerability of agalsidase alfa in patients with Fabry disease who were treatment-naïve or formerly treated with agalsidase beta or agalsidase alfa. J Inherit Metab Dis 2015; EPub ahead of print
   Google Scholar
• Goker-Alpan O, Nedd K, Shanker SP, et al. Reduction of plasma globotriaosylsphingosine levels after switching from agalsidase alfa to agalsidase beta as enzyme replacement therapy for Fabry disease. J Inherit Dis 2015; In Press
   Google Scholar
• Pisani A, Spinelli L, Visciano B, et al. Effects of switching from algalsidase beta to agalsidase alfa in 10 patients with Anderson Fabry disease. JIMD Rep 2013;9:41-8
   PubMedGoogle Scholar
• Tsuboi K, Yamamoto H, Somura F, Goto H. Successful management of enzyme replacement therapy in related fabry disease patients with severe adverse events by switching from agalsidase Beta (fabrazyme(®)) to agalsidase alfa (replagal (®). JIMD Rep 2015;15:105-11
   PubMedGoogle Scholar
• Lin HY, Huang YH, Liao HC, et al. Clinical observations on enzyme replacement therapy in patients with Fabry disease and the switch from agalsidase beta to alfa. J Chin Med Assoc 2014;77(4):190-7
   PubMed Web of Science ®Google Scholar
• Weidemann F, Krämer J, Duning T, et al. Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch. J Am Soc Nephrol 2014;25(4):837-49
   PubMed Web of Science ®Google Scholar
• Tondel C, Bostad L, Larsen KK, et al. Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol 2013;24(1):137-48
   PubMed Web of Science ®Google Scholar
• Warnock DG1, Mauer M. Fabry disease: dose matters. J Am Soc Nephrol 2014;25(4):653-5
   PubMed Web of Science ®Google Scholar
• Clarke JT, West ML, Bultas J, Schiffmann R. The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease. Genet Med 2007;9:504-9
   PubMed Web of Science ®Google Scholar
• Hughes DA, Deegan PB, Milligan A, et al. A randomised, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of three dosing schedules of agalsidase alfa enzyme replacement therapy for Fabry disease. Mol Genet Metab 2013;109(3):269-75
   PubMed Web of Science ®Google Scholar
• Schiffman R, Swift C, Wang X, et al. A prospective 10 year study of individualised intensified enzyme repalcement therapy in Fabry disease. J Inherit Metab Dis 2015; Epub ahead of print
   Google Scholar
• Schiffmann R, Martin RA, Reimschisel T, et al. Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease. J Pediatr 2010;156:832-7
   PubMed Web of Science ®Google Scholar
• Pintos-Morell G, Beck M. Fabry disease in children and the effects of enzyme replacement treatment. Eur J Pediatr 2009;1355-63
   PubMed Web of Science ®Google Scholar
• Ramaswami U, Wendt S, Pintos-Morell G, et al. Enzyme replacement therapy with agalsidase alfa in children with Fabry disease. Acta Paediatr 2007;96:122-7
   PubMed Web of Science ®Google Scholar
• Wraith JE, Tylki-Szymanska A, Gufo N, et al. Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international open-label study in paediatric patients with Fabry disease. J Pediatr 2008;152(4):563-70
   PubMed Web of Science ®Google Scholar
• Wijburg FA, Bénichou B, Bichet DG, et al. Characterization of early disease status in treatment-naive male paediatric patientswith fabry disease enrolled in a randomized clinical trial. PLoS One 2015;10(5):e0124987
   PubMed Web of Science ®Google Scholar
• Wilcox WR, Linthorst G, Germain DP, et al. Anti–alpha-galactosidase A antibody response to agalsidase beta treatment; Data from the Fabry Registry. Mol Genet Metab 2012;105(3):443-9
   PubMed Web of Science ®Google Scholar
• Rombach SM, Aerts JM, Poorthuis BJ, et al. Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome. PLoS One 2012;7(10):e47805
   PubMed Web of Science ®Google Scholar
• Lenders M, Stypmann J, Duning T, et al. Serum-mediated inhibitors of enzyme replacement therapy in Fabry disease. J Am Soc Nephrol 2015; Epub ahead of print
   Google Scholar
• Sims K, Politei J, Banikazemi M, Lee P. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events. Natural history data from the Fabry registry. Stroke 2009;40:788-94
   PubMed Web of Science ®Google Scholar
• Rolfs A, Bottcher T, Zschiesche M. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 2005;366:1794-6
   PubMed Web of Science ®Google Scholar
• Lenders M, Karabul N, Dunting T, et al. Thromboembolic events in Fabry disease and the impact of factor V Leiden. Neurology 2015;84(10):1009-16
   PubMed Web of Science ®Google Scholar
• Schiffmann R, Ries M, Askari H, et al. Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement. Virchows Arch 2006;448(3):337-43
   PubMed Web of Science ®Google Scholar
• Shen J-S, Meng X-L, Moore DF, et al. Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol Genet Metab 2008;95(3):163-8
   PubMed Web of Science ®Google Scholar
• Kaneski CR, Moore DF, Ries M, et al. Myeloperoxidase predicts risk of vasculopathic events in hemizgygous males with Fabry disease. Neurology 2006;67:2045-7
   PubMed Web of Science ®Google Scholar
• Hilz MJ, Kolodny EH, Brys M, et al. Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease. J Neurol 2004;251(5):564-70
   PubMed Web of Science ®Google Scholar
• Moore DF, Altarescu G, Ling GS, et al. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 2002;33(2):525-31
   PubMed Web of Science ®Google Scholar
• Uçeyler N, He L, Kahn AK, et al. Cerebral blood flow in patients with Fabry disease as measured by Doppler sonography is not different from that in healthy individuals and is unaffected by treatment. J Ultrasound Med 2012;31(3):463-8
   PubMed Web of Science ®Google Scholar
• Fellgiebel A, Gartenschlager M, Wildberger K, et al. Enzyme replacement therapy stabilised white matter lesion progression in Fabry disease. Cerebrovascular Dis 2014;448-4
   PubMed Web of Science ®Google Scholar
• Politei J. Can we use statins to prevent stroke in Fabry disease? J Inherit Metab Dis 2009;32(4):481-7
   PubMed Web of Science ®Google Scholar
• Fan JQ, Ishii S, Asano N, Suzuki Y. Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med 1999;5:112-15
   PubMed Web of Science ®Google Scholar
• Germain DP, Giugliani R, Hughes DA, et al. Safety and pharmacodynamic effects of a pharmacological chaperone on alpha-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies. Orphanet J Rare Dis 2012;7:91
   PubMed Web of Science ®Google Scholar
• Amicus Therapeutics provides positive global regulatory updates from EMA and FOA meetings for Fabry monotherapy. 2015. Available from: www.fabry.org/fsig.nsf/PDFs/PDFsIS/$File/Fabry_Mono_Update.pdf [Last accessed 12 May 2015]
   Google Scholar
• Young-Gqamana B, Brignol N, Chang HH, et al. Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients. PLoS One 2013;8(3):e57631
   PubMed Web of Science ®Google Scholar
• Xu S, Lun Y, Brignol N, Hamler R. Co-formulation of a novel human alpha-galactosidase a with the pharmacological chaperone AT1001 leads to improved substrate reduction in Fabry mice. Mol Ther 2015;23(7):1169-81
   PubMed Web of Science ®Google Scholar
• Pisani A, Porto C, Andria G, Pareneti G. Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and agalsidase alpha in cultured fibroblasts from patients with Fabry. J Inherit Metab Dis 2014;37(1):145-6
   PubMed Web of Science ®Google Scholar
• Mistry PK, Lukina E, Ben Turkia H, et al. Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial. JAMA 2015;313(7):695-706
   PubMed Web of Science ®Google Scholar
• Ashe KM, Budman E, Bangari DS, et al. Efficacy of enzyme and substrate reduction therapy with a novel antagonist of glucosylceramide synthase for Fabry disease. Mol Med 2015; in press
   PubMed Web of Science ®Google Scholar
• Sanchez-Nino MD, Sanz AB, Carrosco S, et al. Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. Nephrol Dial Transplant 2011;26(6):1797-802
   PubMed Web of Science ®Google Scholar
• Mechler K, Mountford WK, Hoffman GF, Ries M. Pressure for drug development in lysosomal storage disorders – a quantitative analysis thirty years beyond the US orphan drug act. Orphanet J Rare Dis 2015;10(1):46
   PubMed Web of Science ®Google Scholar
• Hughes DA, Malmenäs M, Deegan PB, et al. Fabry International Prognostic Index: a predictive severity score for Anderson-Fabry disease. J Med Genet 2012(3):212-20
   PubMed Web of Science ®Google Scholar
• Löhle M, Hughes D, Milligan A, et al. Clinical Prodromes of neurodegeneration in Anderson Fabry disease. Neurology 2015;84(14):1454-64
   PubMed Web of Science ®Google Scholar
• Rombach SM, Hollak CE, Linthorst GE, Dijkgraaf MG. Cost-effectiveness of enzyme replacement therapy for Fabry disease. Orphanet J Rare Dis 2013;8:29
   PubMed Web of Science ®Google Scholar
• Kim CO, Oh ES, Park MS. First–in–human study with a new recombinant agalsidase beta (ISU303) in healthy subjects. J Clin Pharmacol 2014;54(6):675-81
   PubMed Web of Science ®Google Scholar
• Kizhner T, Azulay Y, Hainrichson M. Characterization of a chemically modified plant cell culture expressed human alfa-Galactosidase A enzyme for treatment of FAbry disease. Mol Genet Metab 2015;111(2):259-67
   Web of Science ®Google Scholar